Van Andel Research Institute, Nonprofits Collaborate on Parkinson’s Treatment Program

1102

Grand Rapids-based Van Andel Research Institute is partnering with the Michael J. Fox Foundation for Parkinson’s Research and The Cure Parkinson’s Trust to help develop nilotinib, a drug used to treat leukemia, which has shown potential as a therapy for Parkinson’s disease.

As part of the partnership, the three organizations plan to design and co-fund a therapeutic development program that includes a clinical trial of nilotinib, which is expected to begin in 2017.

“It is imperative that we work urgently with the Parkinson’s community — my fellow patients, as well as drug developers — as we continue vetting nilotinib’s potential to address the medical needs of people with Parkinson’s in a safe and effective manner,” says Tom Isaacs, co-founder of The Cure Parkinson’s Trust. 

He says preclinical studies have shown that nilotinib may protect neuronal cells in Parkinson’s patients by inhibiting the activity of a protein known as c-Abl. The protein works as a cancer driver in myelogenous leukemia, and recent work in the field has demonstrated it may also play a role in Parkinson’s disease.

The goal of the collaboration is to advance nilotinib as a potentially disease-modifying or symptomatic Parkinson’s treatment by expanding on early safety findings and potential side effects to better understand long-term use of the drug in non-cancer patients.

Established in 1996, the Van Andel Institute is an independent biomedical research and science education organization that supports the work of more than 360 scientists, educators, and staff. 

Facebook Comments